ALK and non-small cell lung carcinoma: Firstly, we conducted an economic modeling analysis by integrating all the relevant data of clinical trials, which allowed us to compare the cost-effectiveness of using brigatinib followed by lorlatinib before chemotherapy option versus reserving these drugs until after chemotherapy in patients with ALK-positive NSCLC.